Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. - Wikidata - thesis-toulmin - TriplyDB

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

http://www.wikidata.org/entity/Q34415371

about

Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy Virotherapy: cancer gene therapy at last?Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Gemini Surfactants Based on Bis-Imidazolium Alkoxy Derivatives as Effective Agents for Delivery of Nucleic Acids: A Structural and Spectroscopic Study Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion.Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.Transduction of Recombinant M3-p53-R12 Protein Enhances Human Leukemia Cell Apoptosis.Oncolytic viruses: a new class of immunotherapy drugs.Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells.Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.Pharmacological activation of wild-type p53 in the therapy of leukemia.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study.VSV based virotherapy in ovarian cancer: the past, the present and …future?Emerging drugs for head and neck cancer.Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms.

P2860

Q26852345-407558FF-DA27-4C62-9DE7-6DA914D2A1EF Q28066228-43F11B0E-94FF-4A2C-8F21-405E4231E163 Q28074691-E9CCC300-8FF7-4FAD-B14A-607B58A1131C Q35786517-7218D484-EDDD-41F9-8A0D-CB890EC74558 Q35862401-8F5F1696-1152-4997-A082-5800DDA0F282 Q36224460-26B61029-9C4D-4E16-A918-36E2F7B2FF1D Q36910793-7660E7B2-6A19-4C69-83D5-D084B9C1FDE3 Q37068043-EE300A7B-3681-494B-A527-12797D55677E Q38577450-3D35A10B-0601-410B-A6DA-A8FE517A6313 Q38754849-67BA438D-F0AB-41C9-8DD1-1FFBBE462233 Q38853700-CF50A1CD-AD1F-44C8-AEFD-07FA26AD1990 Q38872029-A3E51EBF-F936-43EE-A2F4-CDF5FF5D6589 Q38889573-0E88BE61-04B1-4AF6-8B31-93756DA2007C Q38934039-D82BD3D8-0035-4BF6-B603-0B1017528C33 Q40156290-4FD5213D-EF8C-47D3-96DF-8DC5BD321CFE Q41441101-56D41529-160D-49E7-81AB-3DE71F03E289 Q45874449-01308F34-76BC-4A2C-B5AE-B44A565D6C83 Q55274460-A1508601-78DE-4841-87A2-7D5D8E2664E7

P2860

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

http://www.wikidata.org/entity/Q34415371

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@ast

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@en

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@nl

type

label

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@ast

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@en

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@nl

prefLabel

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@ast

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@en

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@nl

P1433

Q34415371-9E476E1C-4EC5-464F-9F72-EA8B3D6DE754

P1476

Q34415371-8A347688-801D-4AAD-B54E-343C412AC734

P2093

Q34415371-14FE8252-9ECF-4A3A-9BB5-74141B424DA8

Q34415371-15920680-506C-4DB8-8500-A8C249DCEFA7

Q34415371-35AC1F4D-5C77-478A-A220-A3E21DE91383

Q34415371-4DAD19A8-647E-48B4-A6A0-0A1141BC9805

Q34415371-81B4C755-662A-4A89-A2C6-421BB93DB173

Q34415371-F87B3AE3-7BD7-4721-92F9-2B9ADD773614

P2860

Q34415371-048E08FA-73B3-4854-A228-F2B1A0705B88

Q34415371-089D28FA-3D74-49AD-8BE7-D6D444EFC6A0

Q34415371-0B4FB49F-1C59-4983-A763-8E688485677E

Q34415371-0C0009A9-E953-4981-9FD1-C1D14C9D5D77

Q34415371-0CB1DE1E-C693-47D0-9B9A-84ABD4488ACD

Q34415371-15D44B41-FA88-4301-9AAC-811A3D136B17

Q34415371-19D4D52A-4F10-4DEB-9F19-11931FD39ED2

Q34415371-1A170EE1-25E3-4D8D-AA0B-6CF21A4C1DE8

Q34415371-25FB71C7-8824-4D99-90A4-1519BFABFF5B

Q34415371-27DC5893-A637-41E0-9D03-514117640EB8

P304

Q34415371-DEE3C204-3F0C-4C18-AA29-5DF9B2886728

P31

Q34415371-9AAA61A5-5962-4534-99AB-50E978169002

P356

Q34415371-68CB96B4-A209-49C5-BEEE-0A187C419800

P407

Q34415371-D99AAE80-E590-4074-A781-E5437490006E

P478

Q34415371-B2D86FBC-AEAE-4470-80DE-CA35E3F3CF33

P577

Q34415371-4D42E9BE-E1B2-44B5-9695-2867E18F46DC

P5875

Q34415371-CBAE617C-A8B6-46C4-8545-344BA71138FB

P698

Q34415371-B349E3CA-6DC1-46C2-9312-747C238EEC7F

P921

Q34415371-86266437-4011-4B08-8988-A52C551BFB3D

Q34415371-A42E45F7-DDEE-4864-A63B-130348472523

P932

Q34415371-E9F73708-8551-400E-A76C-C1E0FC18C923

P356

P1433

OncoTargets and Therapy

P1476

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

@en

P2093

Chao Ma

http://www.w3.org/2001/XMLSchema#string

Guang-Xia Chen

http://www.w3.org/2001/XMLSchema#string

Shi-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Shu Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao-Hua He

http://www.w3.org/2001/XMLSchema#string

Xiao-Ping Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.

Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Modeling the therapeutic efficacy of p53 restoration in tumors.

A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology

Awakening guardian angels: drugging the p53 pathway.

Tumor suppressor gene therapy.

Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

P304

1901-1909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S50483

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267754351

http://www.w3.org/2001/XMLSchema#string

P698

25364261

http://www.w3.org/2001/XMLSchema#string

P921

P932

4211860

http://www.w3.org/2001/XMLSchema#string